These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28325666)

  • 1. Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor-Resistant Clear Cell Renal Cell Carcinoma.
    Jang J; Rath O; Schueler J; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Kwon GY; Park WY; Lee J; Park SH
    Transl Oncol; 2017 Jun; 10(3):304-310. PubMed ID: 28325666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies.
    Gürgen D; Becker M; Dahlmann M; Flechsig S; Schaeffeler E; Büttner FA; Schmees C; Bohnert R; Bedke J; Schwab M; Wendler JJ; Schostak M; Jandrig B; Walther W; Hoffmann J
    Front Oncol; 2022; 12():889789. PubMed ID: 35800063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-derived cell models as preclinical tools for genome-directed targeted therapy.
    Lee JY; Kim SY; Park C; Kim NK; Jang J; Park K; Yi JH; Hong M; Ahn T; Rath O; Schueler J; Kim ST; Do IG; Lee S; Park SH; Ji YI; Kim D; Park JO; Park YS; Kang WK; Kim KM; Park WY; Lim HY; Lee J
    Oncotarget; 2015 Sep; 6(28):25619-30. PubMed ID: 26296973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma.
    Karam JA; Zhang XY; Tamboli P; Margulis V; Wang H; Abel EJ; Culp SH; Wood CG
    Eur Urol; 2011 Apr; 59(4):619-28. PubMed ID: 21167632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a Novel PDX Mouse Model and Evaluation of the Tumor Suppression Efficacy of Bortezomib Against Liposarcoma.
    Jo EB; Hong D; Lee YS; Lee H; Park JB; Kim SJ
    Transl Oncol; 2019 Feb; 12(2):269-281. PubMed ID: 30447641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
    Oh DY; Jung K; Song JY; Kim S; Shin S; Kwon YJ; Oh E; Park WY; Song SY; Choi YL
    BMC Cancer; 2017 Aug; 17(1):535. PubMed ID: 28806950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery.
    Li J; Pohl L; Schüler J; Korzeniewski N; Reimold P; Kaczorowski A; Hou W; Zschäbitz S; Nientiedt C; Jäger D; Hohenfellner M; Duensing A; Duensing S
    Biomedicines; 2021 May; 9(6):. PubMed ID: 34072926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and Preclinical Patient-Derived Model Studies Define High Expression of NRN1 as a Diagnostic and Therapeutic Target for Clear Cell Renal Cell Carcinoma.
    Kamada S; Ikeda K; Suzuki T; Sato W; Kitayama S; Kawakami S; Ichikawa T; Horie K; Inoue S
    Front Oncol; 2021; 11():758503. PubMed ID: 34804954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.
    Roscilli G; De Vitis C; Ferrara FF; Noto A; Cherubini E; Ricci A; Mariotta S; Giarnieri E; Giovagnoli MR; Torrisi MR; Bergantino F; Costantini S; Fenizia F; Lambiase M; Aurisicchio L; Normanno N; Ciliberto G; Mancini R
    J Transl Med; 2016 Feb; 14():61. PubMed ID: 26928703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 induces drug resistance in renal cell carcinoma.
    Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
    Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
    Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
    J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors.
    Na YS; Ryu MH; Yoo C; Lee JK; Park JM; Lee CW; Lee SY; Shin YK; Ku JL; Ahn SM; Kang YK
    Oncotarget; 2017 Sep; 8(44):76712-76721. PubMed ID: 29100343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer.
    Kamli H; Li L; Gobe GC
    Ochsner J; 2019; 19(2):138-151. PubMed ID: 31258426
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
    Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
    Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer.
    Chen Z; Huang W; Tian T; Zang W; Wang J; Liu Z; Li Z; Lai Y; Jiang Z; Gao J; Shen L
    J Hematol Oncol; 2018 Feb; 11(1):20. PubMed ID: 29433585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
    Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
    Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models.
    Reguera-Nuñez E; Man S; Xu P; Kerbel RS
    Angiogenesis; 2018 Nov; 21(4):793-804. PubMed ID: 29786782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts.
    Kuwata T; Yanagihara K; Iino Y; Komatsu T; Ochiai A; Sekine S; Taniguchi H; Katai H; Kinoshita T; Ohtsu A
    Cells; 2019 Jun; 8(6):. PubMed ID: 31207870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis.
    Karashima T; Fukuhara H; Tamura K; Ashida S; Kamada M; Inoue K; Taguchi T; Kuroda N; Shuin T
    Int J Urol; 2013 Sep; 20(9):923-30. PubMed ID: 23379954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.